Search

Your search keyword '"METAL TRANSPORTER 1"' showing total 3 results
Start Over Descriptor "METAL TRANSPORTER 1"
3 results on '"METAL TRANSPORTER 1"'

1. Targeting iron metabolism in drug discovery and delivery

Author

Bart J Crielaard, Twan Lammers, and Stefano Rivella

Subjects
0301 basic medicine, HUMAN HEPATOMA-CELLS, Iron, Hemoglobin Scavenger Receptor, HYDROXYLASE DOMAIN PROTEIN-2, Pharmacology, Biology, Article, AMYOTROPHIC-LATERAL-SCLEROSIS, 03 medical and health sciences, Drug Delivery Systems, Iron homeostasis, Neoplasms, Drug Discovery, METAL TRANSPORTER 1, Animals, Homeostasis, Humans, Molecular Targeted Therapy, AUTOSOMAL-DOMINANT HEMOCHROMATOSIS, REPULSIVE GUIDANCE MOLECULE, BONE MORPHOGENETIC PROTEIN, Physiological control, Drug discovery, Neurodegenerative Diseases, General Medicine, Metabolism, Human physiology, 3. Good health, TUMOR-ASSOCIATED MACROPHAGES, BETA-THALASSEMIA-INTERMEDIA, 030104 developmental biology, Drug Design, HEMOGLOBIN SCAVENGER RECEPTOR, Clinical evaluation, Haematological disorders
Abstract

Iron fulfils a central role in many essential biochemical processes in human physiology, which makes proper processing of iron crucial. Although iron metabolism is subject to relatively strict physiological control, in recent years numerous disorders, such as cancer and neurodegenerative diseases, have been linked to deregulated iron homeostasis. Because of its involvement in the pathogenesis of these diseases, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents will likely have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are often available.

Published
2017

2. Targeting iron metabolism in drug discovery and delivery

Subjects
BONE MORPHOGENETIC PROTEIN, HUMAN HEPATOMA-CELLS, TUMOR-ASSOCIATED MACROPHAGES, BETA-THALASSEMIA-INTERMEDIA, METAL TRANSPORTER 1, HEMOGLOBIN SCAVENGER RECEPTOR, HYDROXYLASE DOMAIN PROTEIN-2, AUTOSOMAL-DOMINANT HEMOCHROMATOSIS, REPULSIVE GUIDANCE MOLECULE, AMYOTROPHIC-LATERAL-SCLEROSIS
Abstract

Iron fulfils a central role in many essential biochemical processes in human physiology; thus, proper processing of iron is crucial. Although iron metabolism is subject to relatively strict physiological control, numerous disorders, such as cancer and neurodegenerative diseases, have recently been linked to deregulated iron homeostasis. Consequently, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments for these diseases. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents are likely to have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are currently available.

Published
2017

3. Placental concentrations of manganese and the risk of fetal neural tube defects.

Author

Liu J, Jin L, Zhang L, Li Z, Wang L, Ye R, Zhang Y, and Ren A

Subjects
Case-Control Studies, Female, Humans, Infant, Newborn, Neural Tube Defects epidemiology, Pregnancy, Risk Factors, Manganese blood, Neural Tube Defects blood, Placenta chemistry
Abstract

Manganese (Mn) is an essential trace element required for normal growth, development, and cellular homeostasis, but excess Mn is toxic to the central nervous system. The present pilot study examined whether the level of Mn in the placenta was associated with the risk of fetal neural tube defects (NTDs). A case-control study was conducted. Cases were 80 fetuses or newborns with NTDs, and controls were 50 healthy, nonmalformed newborns. Placental Mn, zinc, copper, iron, and selenium were determined with inductively coupled plasma-mass spectrometry. The median Mn concentration was significantly higher in case placentas than in controls: cases, 131.60 ng/g (95% confidence interval [CI], 99.25-166.76); controls, 101.54 ng/g (95% CI, 80.14-119.79). Mn concentrations above the median were associated with a 4-fold (95% CI, 1.23-14.79) increased risk for any NTDs and a 7-fold (95% CI, 1.52-39.64) increased risk for spina bifida after other confounding factors were controlled. Elevated Mn levels were associated with an increased risk of anencephaly, although the adjusted odds ratio did not reach statistical significance. The association between higher Mn concentrations and risk of NTDs showed a clear dose-response relationship. Risk of NTDs increased to 1.51 (95% CI, 0.65-3.52) and 5.03 (95% CI, 1.89-13.33) for those whose placental Mn level was in the second and third tertiles, respectively, compared with the lowest tertile. Elevated placental concentrations of Mn may be associated with increased risks of NTDs in this population., (Copyright © 2013 Elsevier GmbH. All rights reserved.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results